Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
Executive Summary
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.
You may also be interested in...
Contrave OK'd in obesity; multiple trials required
Orexigen Therapeutics' and Takeda's anti-obesity drug Contrave (naltrexone SR/bupropion SR) was finally approved by the FDA on 10 September, but not without its many trials and tribulations along the way.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, including Genmab/AbbVie’s Tepkinly, for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.